Phase II Study of Single-Agent and Combination Everolimus and Panobinostat in Relapsed or Refractory Diffuse Large B-Cell Lymphoma-Reference-Cited by-同舟云学术

Phase II Study of Single-Agent and Combination Everolimus and Panobinostat in Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Published:2021-10-13 Issue:10 Volume:39 Page:871-879
ISSN:0735-7907
Container-title:Cancer Investigation
language:en
Short-container-title:Cancer Investigation

Author:

Islam Prioty¹,Rizzieri David¹,Lin Chenyu¹,de Castro Carlos¹,Diehl Louis¹,Li Zhiguo²,Moore Joseph¹,Morris Tod¹,Beaven Anne¹³^ORCID

Affiliation:

1. Division of Hematologic Malignancies and Cellular Therapy, Duke University Medical Center, Durham, North Carolina, USA

2. Duke Cancer Institute, Biostatistics Shared Resources, Duke University, Durham, North Carolina, USA

3. Division of Hematology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA

Funder

Novartis Pharmaceuticals

NIH/NHLBI T32

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/07357907.2021.1983584

Reference24 articles.

1. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H. WHO classification of tumours of haematopoietic and lymphoid tissues, fourth edition. Lyon, France: IARC; 2008.

2. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte

3. Clinical Outcome following Autologous and Allogeneic Blood and Marrow Transplantation for Relapsed Diffuse Large-Cell Non-Hodgkin’s Lymphoma

4. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study

5. A Comparison of 2-Year Outcomes in ZUMA-1 (Axicabtagene Ciloleucel [Axi-Cel]) and SCHOLAR-1 in Patients (Pts) with Refractory Large B Cell Lymphoma (LBCL)

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Unraveling the Immune Microenvironment in Diffuse Large B-Cell Lymphoma: Prognostic and Potential Therapeutic Implications;Current Issues in Molecular Biology;2024-07-05

2. Advances of Epigenetic DNA Methylation and Histone Modifications in DLBCL;Advances in Clinical Medicine;2024

3. Technologies of targeting histone deacetylase in drug discovery: Current progress and emerging prospects;European Journal of Medicinal Chemistry;2023-12

4. The Role of mTOR in B Cell Lymphoid Malignancies: Biologic and Therapeutic Aspects;International Journal of Molecular Sciences;2023-09-14

5. PNOC015: Repeated convection-enhanced delivery of MTX110 (aqueous panobinostat) in children with newly diagnosed diffuse intrinsic pontine glioma;Neuro-Oncology;2023-06-15